1. Home
  2. Press release
Jun 03, 2022 16:37 JST

Source: Eisai

Eisai to Present Latest Data on Lemborexant at The 36th Annual Sleep 2022 Meeting

TOKYO, Jun 03, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced a total of seven poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 36th annual meeting of the Associated Professional Sleep Societies (SLEEP 2022), to be held from June 4 to 8, 2022, in Charlotte, NC, the United States.

Major poster presentations include the results of a subgroup analysis of the Phase III 304 clinical study on the effect of lemborexant treatment in older adults with insomnia and objectives of short sleep which is characterized by sleeping fewer than six hours (Posters #171 and #172).

"DAYVIGO continues to serve as an important asset to Eisai's neurology portfolio and we look forward to presenting the findings from several analyses at this year's SLEEP Meeting," said Ivan Cheung, Eisai Inc., Senior Vice President, President Neurology Business Group, Eisai Co., Ltd. "Insomnia can lead to daytime consequences; fatigue, difficulty concentrating and irritability,(1),(2) and causes distress or impairs functioning in social and occupational settings. Eisai remains committed to our pursuit of helping people suffering from insomnia to help address unmet medical needs."

(1) Ferrie JE, et al. Sleep epidemiology - a rapidly growing field. Int J Epidemiol. 2011;40(6):1431-1437.
(2) Roth T. Insomnia: definition, prevalence, etiology and consequences. J Clin Sleep Med. 2007;3(5 Suppl):S7-S10

About Lemborexant (product name: DAYVIGO)

Lemborexant, an orexin receptor antagonist, is Eisai's in-house discovered and developed small molecule that inhibits orexin neurotransmission by binding competitively to the two subtypes of orexin receptors (orexin receptor 1 and 2). Fast on/off receptor kinetics of lemborexant to orexin receptors may influence lemborexant's potential to facilitate improvements in sleep onset and maintenance with minimal morning residual effects. It has been approved for the treatment of insomnia in over 10 countries including Japan, the United States and countries in Asia.

For more information, visit www.eisai.com/news/2022/news202244.html.

Source: Eisai
Sectors: BioTech

Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
November 28 2025 22:00 JST
 
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
November 26 2025 18:42 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
November 17 2025 21:08 JST
 
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
October 30 2025 13:43 JST
 
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
October 28 2025 23:30 JST
 
Health Canada Grants Authorization for "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease
October 27 2025 13:23 JST
 
LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
October 14 2025 16:54 JST
 
Eisai and Biogen Announce U.S. Availability of LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
October 08 2025 11:03 JST
 
Eisai Highlights Breadth of Oncology Research at ESMO 2025
October 03 2025 17:01 JST
 
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in China
September 29 2025 09:33 JST
 
More Press release >>

Latest Press Release


Anime Tokyo Station: Celebrating the 25th Anniversaries of Two Popular Anime with an Anniversary Joint Exhibition Starting November 15
Dec 03, 2025 11:30 JST

Fujitsu achieves high-precision, long-duration molecular dynamics simulation for all-solid-state battery interphases with over 100,000 atoms
Dec 01, 2025 23:04 JST

Fujitsu develops multi-AI agent collaboration technology to optimize supply chains, launches joint trials
Dec 01, 2025 22:43 JST

Fujitsu launches 'Fujitsu Accelerator Program for SPORTS' to create new value through Sports x Technology
Dec 01, 2025 22:14 JST

Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 28, 2025 23:00 JST

JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Nov 28, 2025 19:41 JST

MHI Publishes "MHI REPORT 2025" and "SUSTAINABILITY DATABOOK 2025"
Nov 28, 2025 19:05 JST

Sharp Wins IAM's "Asia IP Elite 2025", Awarded to Companies with Outstanding Intellectual Property Strategy for The Second Consecutive Year
Nov 28, 2025 18:36 JST

Fujitsu builds platform for NSK to create environmental value throughout the product lifecycle of bearing products
Nov 28, 2025 18:01 JST

Fujitsu launches Japan Edition of SAP Fioneer Cloud for Insurance, a next-generation platform supporting core business operations in the Japanese insurance industry
Nov 28, 2025 17:28 JST

NEC Launches Sales Support Solution Utilizing Agentic AI
Nov 27, 2025 22:31 JST

Fujitsu and Yamaguchi University develop low-power edge computing technology for near real-time image processing on small satellites
Nov 27, 2025 22:00 JST

World's first ever spiral escalator renewal project conducted at a commercial facility in Mexico
Nov 27, 2025 11:00 JST

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 26, 2025 19:42 JST

Fujitsu accelerates blue carbon certification with ocean digital twin technology
Nov 26, 2025 19:05 JST

Fujitsu recognized with two Microsoft Japan Partner of the Year awards
Nov 26, 2025 18:40 JST

Xforce HEV Model Wins Thailand Car of the Year 2025
Nov 26, 2025 18:00 JST

Mitsubishi Motors Launches the All-New Destinator in the Philippine Market
Nov 25, 2025 14:36 JST

New Corporate Slogan "In step with your future."
Nov 25, 2025 13:51 JST

MHI Receives EPC Contract for Cyclo Olefin Polymer Plant for Zeon Corporation
Nov 25, 2025 13:13 JST
 More Latest Release >>